Healthcare

Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 2018–2025

  • ALL3201247
  • 171 Pages
  • May 2019
  • Healthcare
Download Sample    Get Discount   
 
The global pneumonia vaccines market was valued at $7,083 million in 2017 and is expected to reach $10,215 million by 2025, growing at a CAGR of 5% from 2018 to 2025.

Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults.

Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.

Thus, Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines, PCV13 and PPSV23. The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the market growth. Moreover, development of protein-based combination pneumococcal vaccines is expected to provide lucrative opportunities for the expansion of this market.

The global pneumonia vaccine market is segmented based on type, product, distribution channel, sector, and region. Based on type, the market is bifurcated into pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPV). Products covered in the study include Synflorix, Prevnar 13, PPSV- 23, PCV 13-PIPELINE, V114-MERCK, PCV-20-PFIZER, and PCV-10-SII. Based on distribution channel, the market is categorized into distribution partner companies, non-governmental organizations (NGO), and government authorities. Based on sector, the market is bifurcated into public and private. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

 The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

 It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

 Analysis by type helps understand the various types of pneumonia vaccines used by healthcare providers.

 Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.

 Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Vaccine Type

• Pneumococcal Conjugate Vaccine

• Pneumococcal Polysaccharide Vaccine

By Product Type

• Prevnar 13

• Synflorix

• Pneumovax 23

By Sector

• Public

• Private

By distribution channel

• Distribution Partner Companies

• Non-governmental Organizations (NGO)

• Government Authorities

By Country

• North America

• Europe

• Asia-Pacific

• LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT (VACCINE PROVIDERS)

• Glaxosmithkline plc.

• LG Chem Ltd.

• Merck & Co., Inc.

• Panacea Biotec Limited

• Pfizer Inc.

• Pnuvax Incorporated

• Serum Institute of India Pvt. Ltd.

• Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)

• SK Bioscience

• Walvax Biotechnology Co., Ltd.

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top winning strategies, 2016–2018

3.2.3. Top strategies:

3.3. Porters five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Threat of new entrants

3.3.3. Threat of substitutes

3.3.4. Competitive rivalry

3.3.5. Bargaining power among buyers

3.4. Market share analysis, 2018

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Surge in prevalence of pneumonia across the globe

3.5.1.2. Rise in government focus on immunization programs for pneumonia

3.5.1.3. Increase in focus for novel pneumococcal vaccines

3.5.2. Restraints

3.5.2.1. Longer timelines required for pneumonia vaccine production

3.5.2.2. High cost associated with development of such vaccines

3.5.3. Opportunity

3.5.3.1. Development of protein-based combination pneumococcal vaccines

CHAPTER 4: PNEUMONIA VACCINES MARKET, BY VACCINE TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Pneumococcal conjugate vaccine (PCV)

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast

4.3. Pneumococcal polysaccharide vaccine (PPSV/PPV)

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast

CHAPTER 5: PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Prevnar 13

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast

5.3. Synflorix

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast

5.4. Pneumovax23

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast

5.5. Pipeline Products

CHAPTER 6: PNEUMONIA VACCINES MARKET, BY SECTOR

6.1. Overview

6.1.1. Market size and forecast

6.2. Public sector

6.2.1. Market size and forecast

6.3. Private sector

6.3.1. Market size and forecast

CHAPTER 7: PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.1.1. Market size and forecast

7.2. Distribution partner companies

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast

7.3. Non-governmental Organizations (NGO)

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast

7.4. Government Authorities

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast

CHAPTER 8: GLOBAL PNEUMONIA MARKET, BY REGION

8.1. Overview

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends

8.2.2. Key growth factors and opportunities

8.2.3. Market size and forecast, by type

8.2.4. Market size and forecast, by product type

8.2.5. Market size and forecast, by distribution channel

8.2.6. Market size and forecast, by sector

8.2.7. Market size and forecast, by country

8.2.7.1. The U.S. Pneumonia Vaccine Market

8.2.7.1.1. Market Size and forecast, by type

8.2.7.1.2. Market Size and forecast, by product type

8.2.7.1.3. Market Size and forecast, by distribution channel

8.2.7.1.4. Market Size and forecast, by sector

8.2.7.2. Canada Pneumonia Vaccine Market

8.2.7.2.1. Market Size and forecast, by type

8.2.7.2.2. Market Size and forecast, by product type

8.2.7.2.3. Market Size and forecast, by distribution channel

8.2.7.2.4. Market Size and forecast, by sector

8.2.7.3. Mexico Pneumonia Vaccine Market

8.2.7.3.1. Market Size and forecast, by type

8.2.7.3.2. Market Size and forecast, by product type

8.2.7.3.3. Market Size and forecast, by distribution channel

8.2.7.3.4. Market Size and forecast, by sector

8.3. Europe

8.3.1. Key market trends

8.3.2. Key growth factors and opportunities

8.3.3. Market size and forecast, by type

8.3.4. Market size and forecast, by product type

8.3.5. Market size and forecast, by distribution channel

8.3.6. Market size and forecast, by sector

8.3.7. Market size and forecast, by country

8.3.7.1. Germany Pneumonia Vaccine Market

8.3.7.1.1. Market Size and forecast, by type

8.3.7.1.2. Market Size and forecast, by product type

8.3.7.1.3. Market Size and forecast, by distribution channel

8.3.7.1.4. Market Size and forecast, by sector

8.3.7.2. France Pneumonia Vaccine Market

8.3.7.2.1. Market Size and forecast, by type

8.3.7.2.2. Market Size and forecast, by product type

8.3.7.2.3. Market Size and forecast, by distribution channel

8.3.7.2.4. Market Size and forecast, by sector

8.3.7.3. UK Pneumonia Vaccine Market

8.3.7.3.1. Market Size and forecast, by type

8.3.7.3.2. Market Size and forecast, by product type

8.3.7.3.3. Market Size and forecast, by distribution channel

8.3.7.3.4. Market Size and forecast, by sector

8.3.7.4. Spain Pneumonia Vaccine Market

8.3.7.4.1. Market Size and forecast, by type

8.3.7.4.2. Market Size and forecast, by product type

8.3.7.4.3. Market Size and forecast, by distribution channel

8.3.7.4.4. Market Size and forecast, by sector

8.3.7.5. Italy Pneumonia Vaccine Market

8.3.7.5.1. Market Size and forecast, by type

8.3.7.5.2. Market Size and forecast, by product type

8.3.7.5.3. Market Size and forecast, by distribution channel

8.3.7.5.4. Market Size and forecast, by sector

8.3.7.6. Rest of Europe Pneumonia Vaccine Market

8.3.7.6.1. Market Size and forecast, by type

8.3.7.6.2. Market Size and forecast, by product type

8.3.7.6.3. Market Size and forecast, by distribution channel

8.3.7.6.4. Market Size and forecast, by sector

8.4. Asia-Pacific

8.4.1. Key market trends

8.4.2. Key growth factors and opportunities

8.4.3. Market size and forecast, by type

8.4.4. Market size and forecast, by product type

8.4.5. Market size and forecast, by distribution channel

8.4.6. Market size and forecast, by sector

8.4.7. Market size and forecast, by country

8.4.7.1. Japan Pneumonia Vaccine Market

8.4.7.1.1. Market Size and forecast, by type

8.4.7.1.2. Market Size and forecast, by product type

8.4.7.1.3. Market Size and forecast, by distribution channel

8.4.7.1.4. Market Size and forecast, by sector

8.4.7.2. China Pneumonia Vaccine Market

8.4.7.2.1. Market Size and forecast, by type

8.4.7.2.2. Market Size and forecast, by product type

8.4.7.2.3. Market Size and forecast, by distribution channel

8.4.7.2.4. Market Size and forecast, by sector

8.4.7.3. India Pneumonia Vaccine Market

8.4.7.3.1. Market Size and forecast, by type

8.4.7.3.2. Market Size and forecast, by product type

8.4.7.3.3. Market Size and forecast, by distribution channel

8.4.7.3.4. Market Size and forecast, by sector

8.4.7.4. Rest of Asia-Pacific Pneumonia Vaccine Market

8.4.7.4.1. Market Size and forecast, by type

8.4.7.4.2. Market Size and forecast, by product type

8.4.7.4.3. Market Size and forecast, by distribution channel

8.4.7.4.4. Market Size and forecast, by sector

8.5. LAMEA

8.5.1. Key market trends

8.5.2. Key growth factors and opportunities

8.5.3. Market size and forecast, by type

8.5.4. Market size and forecast, by product type

8.5.5. Market size and forecast, by distribution channel

8.5.6. Market size and forecast, by sector

8.5.7. Market size and forecast, by country

8.5.7.1. Brazil Pneumonia Vaccine Market

8.5.7.1.1. Market Size and forecast, by type

8.5.7.1.2. Market Size and forecast, by product type

8.5.7.1.3. Market Size and forecast, by distribution channel

8.5.7.1.4. Market Size and forecast, by sector

8.5.7.2. South Africa Pneumonia Vaccine Market

8.5.7.2.1. Market Size and forecast, by type

8.5.7.2.2. Market Size and forecast, by product type

8.5.7.2.3. Market Size and forecast, by distribution channel

8.5.7.2.4. Market Size and forecast, by sector

8.5.7.3. Saudi Arabia Pneumonia Vaccine Market

8.5.7.3.1. Market Size and forecast, by type

8.5.7.3.2. Market Size and forecast, by product type

8.5.7.3.3. Market Size and forecast, by distribution channel

8.5.7.3.4. Market Size and forecast, by sector

8.5.7.4. Rest of LAMEA Pneumonia Vaccine Market

8.5.7.4.1. Market Size and forecast, by type

8.5.7.4.2. Market Size and forecast, by product type

8.5.7.4.3. Market Size and forecast, by distribution channel

8.5.7.4.4. Market Size and forecast, by sector

CHAPTER 9: COMPANY PROFILES

9.1. GLAXOSMITHKLINE PLC.

9.1.1. Company overview

9.1.2. Company snapshot

9.1.3. Operating business segments

9.1.4. Product Portfolio

9.1.5. Business performance

9.2. LG CHEM LTD.

9.2.1. Company overview

9.2.2. Company snapshot

9.2.3. Operating business segments

9.2.4. Product portfolio

9.2.5. Business performance

9.3. MERCK & CO., INC.

9.3.1. Company overview

9.3.2. Company snapshot

9.3.3. Operating business segments

9.3.4. Product Portfolio

9.3.5. Business performance

9.4. PANACEA BIOTEC LIMITED

9.4.1. Company overview

9.4.2. Company snapshot

9.4.3. Operating business segments

9.4.4. Product portfolio

9.4.5. Business performance

9.5. PFIZER INC.

9.5.1. Company overview

9.5.2. Company snapshot

9.5.3. Operating business segments

9.5.4. Product portfolio

9.5.5. Business performance

9.6. PNUVAX INCORPORATED

9.6.1. Company overview

9.6.2. Company snapshot

9.6.3. Product portfolio

9.7. SERUM INSTITUTE OF INDIA PVT. LTD.

9.7.1. Company overview

9.7.2. Company snapshot

9.7.3. Product portfolio

9.8. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)

9.8.1. Company overview

9.8.2. Company snapshot

9.8.3. Product portfolio

9.9. SK BIOSCIENCE

9.9.1. Company overview

9.9.2. Company snapshot

9.9.3. Product portfolio

9.10. WALVAX BIOTECHNOLOGY CO., LTD.

9.10.1. Company overview

9.10.2. Company snapshot

9.10.3. Product Portfolio

LIST OF TABLES

TABLE 01. PNEUMONIA VACCINES MARKET, BY VACCINE TYPE, 2017–2025 ($MILLION)

TABLE 02. PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL CONJUGATE VACCINES, BY REGION, 2017–2025 ($MILLION)

TABLE 03. PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL POLYSACCHARIDE VACCINES, BY REGION, 2017–2025 ($MILLION)

TABLE 04. PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 05. PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY REGION, 2017–2025 ($MILLION)

TABLE 06. PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY TARGET POPULATION, 2017–2025 ($MILLION)

TABLE 07. PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY REGION, 2017–2025 ($MILLION)

TABLE 08. PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY TARGET POPULATION, 2017–2025 ($MILLION)

TABLE 09. PNEUMONIA VACCINE MARKET FOR PNEUMOVAX23, BY REGION, 2017–2025 ($MILLION)

TABLE 10. PNEUMONIA VACCINE MARKET FOR PNEUMOVAX, BY TARGET POPULATION, 2017–2025 ($MILLION)

TABLE 11. PNEUMONIA VACCINE PRODUCT PIPELINE

TABLE 12. PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 13. PNEUMONIA VACCINE MARKET BY PUBLIC SECTOR, 2017–2025 ($MILLION)

TABLE 14. PNEUMONIA VACCINE MARKET, BY PRIVATE SECTOR, 2017–2025 ($MILLION)

TABLE 15. PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 16. PNEUMONIA VACCINE MARKET FOR DISTRIBUTION PARTNER COMPANIES, BY REGION, 2017–2025 ($MILLION)

TABLE 17. PNEUMONIA VACCINE MARKET FOR NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2017–2025 ($MILLION)

TABLE 18. PNEUMONIA VACCINE MARKET FOR GOVERNMENT AUTHORITIES, BY REGION, 2017–2025 ($MILLION)

TABLE 19. PNEUMONIA VACCINE MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 20. NORTH AMERICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 21. NORTH AMERICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 22. NORTH AMERICAPNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 23. NORTH AMERICAPNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 24. NORTH AMERICA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 25. THE U.S. PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 26. THE U.S. PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 27. THE U.S. PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 28. THE U.S. PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 29. CANADA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 30. CANADA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 31. CANADA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 32. CANADA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 33. MEXICO PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 34. MEXICO PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 35. MEXICO PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 36. MEXICO PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 37. EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 38. EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 39. EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 40. EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 41. EUROPE PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 42. GERMANY PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 43. GERMANY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 44. GERMANY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 45. GERMANY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 46. FRANCE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 47. FRANCE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 48. FRANCE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 49. FRANCE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 50. UK PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 51. UK PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 52. UK PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 53. UK PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 54. SPAIN PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 55. SPAIN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 56. SPAIN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 57. SPAIN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 58. ITALY PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 59. ITALY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 60. ITALY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 61. ITALY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 62. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 63. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 64. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 65. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 66. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 67. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 68. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 69. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 70. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 71. JAPAN PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 72. JAPAN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 73. JAPAN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 74. JAPAN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 75. CHINA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 76. CHINA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 77. CHINA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 78. CHINA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 79. INDIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 80. INDIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 81. INDIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 82. INDIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 83. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 84. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 85. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 86. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 87. LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 88. LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 89. LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 90. LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 91. LAMEA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 92. BRAZIL PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 93. BRAZIL PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 94. BRAZIL PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 95. BRAZIL PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 96. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 97. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 98. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 99. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 100. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 101. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 102. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 103. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 104. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 105. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)

TABLE 106. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)

TABLE 107. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)

TABLE 108. GSK: COMPANY SNAPSHOT

TABLE 109. GSK: OPERATING SEGMENTS

TABLE 110. GSK: PRODUCT PORTFOLIO

TABLE 111. LG CHEM: COMPANY SNAPSHOT

TABLE 112. LG CHEM: OPERATING SEGMENTS

TABLE 113. KINDER MORGAN: PRODUCT PORTFOLIO

TABLE 114. MERCK: COMPANY SNAPSHOT

TABLE 115. MERCK: OPERATING SEGMENTS

TABLE 116. MERCK: PRODUCT PORTFOLIO

TABLE 117. PANACEA BIOTEC: COMPANY SNAPSHOT

TABLE 118. PANACEA BIOTEC: OPERATING SEGMENTS

TABLE 119. PANACEA BIOTEC: PRODUCT PORTFOLIO

TABLE 120. PFIZER: COMPANY SNAPSHOT

TABLE 121. PFIZER: OPERATING SEGMENTS

TABLE 122. PFIZER: PRODUCT PORTFOLIO

TABLE 123. PNUVAX: COMPANY SNAPSHOT

TABLE 124. PNUVAX: PRODUCT PORTFOLIO

TABLE 125. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT

TABLE 126. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO

TABLE 127. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: COMPANY SNAPSHOT

TABLE 128. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: PRODUCT PORTFOLIO

TABLE 129. SK BIOSCIENCE: COMPANY SNAPSHOT

TABLE 130. SK BIOSCIENCE: PRODUCT PORTFOLIO

TABLE 131. WALVAX: COMPANY SNAPSHOT

TABLE 132. WALVAX: PRODUCT PORTFOLIO

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Similar Reports

Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, and Pharmaceutical), and Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...

  • Publish Date: May 29, 2018
  • $5370
World Medical Robotics and Computer - Assisted Surgery Market - Opportunities and Forecasts, 2015 - 2022

The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...

  • Publish Date: May 1, 2016
  • $5370